The FDA on March 31, 2021 approved SARCLISA® in combination with KYPROLIS® (Carfilzomib) and Dexamethasone, for the treatment of adult patients with Relapsed or Refractory Multiple Myeloma who have received one to three prior lines of therapy. SARCLISA® is a product of Sanofi-Aventis U.S. LLC.
Bottom Ad
Advertisement
Subscribe
